本文已被：浏览 2552次 下载 15次
中文摘要: 目的 分析胰激肽原酶肠溶片联合肾炎康复片治疗糖尿病早期肾病的临床疗效。方法 选取2016年1月—11月在金桥社区卫生服务中心糖尿病专科门诊就诊的糖尿病早期肾病患者80例，随机分为A、B、C三组，A组(23例)仅应用降血糖药物，B组(26例)应用降糖药物及肾炎康复片，C组(31例)在B组的基础上加服胰激肽原酶肠溶片，观察服药前及服药6个月后的临床疗效及空腹血糖(GLU)，人尿微量白蛋白(U-MA)、血尿素氮(BUN)和血清胱抑素C(Cystatin C)测定值的变化。结果 C组患者在服药6个月后临床有效率显著高于A组与B组(P＜0.05)，GLU、m-ALB、BUN和Cystatin C测定值显著低于A组和B组(P＜0.05)。结论 胰激肽原酶肠溶片联合肾炎康复片治疗糖尿病早期肾病疗效安全显著，值得临床推广应用。
Abstract:OBJECTIVE To analyze the clinical efficacy of pancreatic kininogenase enteric-coated tablets combined with nephritis rehabilitation tablets in the treatment of early diabetic nephropathy. METHODS Eighty patients with early diabetic nephropathy were randomly divided into three groups:group A,group B and group C.The patients with group A(23 cases)received only hypoglycemic agents,Group B(26 cases)was treated with hypoglycemic drugs and nephritis rehabilitation tablets,group C(31 cases)group B was supplemented with pancreatic kininase enteric-coated tablets,before and after taking the drug for 6 months(GLU),human urine microalbumin(m-ALB),blood urea nitrogen(BUN)and serum cystatin C(Cystatin C)were measured. RESULTS The clinical efficacy of group A and group B was significantly higher than that of group A and group B(P＜0.05).The levels of GLU,m-ALB,BUN and Cystatin C were significantly lower in group C and group B(P＜0.05). CONCLUSION The therapeutic effect of pancreatic kininogenin enteric-coated tablets combined with nephritis rehabilitation tablets on the treatment of early diabetic nephropathy is significant and worthy of clinical application.
文章编号：3201804030 中图分类号：R977.1+5 文献标志码：
基金项目:
| Author Name | Affiliation |
引用文本：